NewAmsterdam Pharma Co N.V. (NAMS) stock
NAMSNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as NAMSW
$19.39−0.07 (-0.36%)
Close on Nov 17, 2026Market cap $2.32BP/E –Yield –
NewAmsterdam Pharma operating margin
Operating margin is operating income as a percentage of revenue.
NewAmsterdam Pharma's operating margin for the twelve months ending Jun 30, 2026 was -3432.2%. For fiscal 2025 it was -1002.9%, against -386.9% the year before.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -1002.9% | −616.0 |
| FY2024 | Dec 31, 2024 | -386.9% | +911.6 |
| FY2023 | Dec 31, 2023 | -1298.6% | −1295.1 |
| FY2022 | Dec 31, 2022 | -3.5% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -1752.6% | −1566.5 |
| Q1 FY2026 | Mar 31, 2026 | -1921.7% | +392.8 |
| Q4 FY2025 | Dec 31, 2025 | -206187.5% | −205849.0 |
| Q3 FY2025 | Sep 30, 2025 | -15845.7% | −15759.8 |
| Q2 FY2025 | Jun 30, 2025 | -186.1% | +2120.8 |
| Q1 FY2025 | Mar 31, 2025 | -2314.5% | +1645.7 |
| Q4 FY2024 | Dec 31, 2024 | -338.5% | +6021.9 |
| Q3 FY2024 | Sep 30, 2024 | -85.9% | +1599.2 |
| Q2 FY2024 | Jun 30, 2024 | -2306.9% | +167.3 |
| Q1 FY2024 | Mar 31, 2024 | -3960.2% | −3498.3 |
| Q4 FY2023 | Dec 31, 2023 | -6360.4% | – |
| Q3 FY2023 | Sep 30, 2023 | -1685.1% | – |
| Q2 FY2023 | Jun 30, 2023 | -2474.2% | – |
| Q1 FY2023 | Mar 31, 2023 | -461.8% | – |
See a number that looks wrong?